41 results about "DNA virus" patented technology

The invention discloses an application of Micropterus salmoides Piscidin polypeptide in preparation of an anti-fish virus drug. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 2 or SEQ ID NO. 3. The research finds that the micropterus salmoides Piscidin is an antibacterial peptide with an antiviral function, the polypeptide synthesized by the artificially synthesized micropterus salmoides Piscidin has the characteristic of inhibiting fish DNA virus replication, has a remarkable inhibiting effect on fish iridovirus replication at low concentration, and can be applied to preparation, research and development of fish antiviral drugs. Research of the antibacterial peptide has important scientific value and application value for further research and development of disease-resistant functional gene products.

The present invention is directed to a method of determining DNA concentration in a DNA virus. The invention features three basic steps. The initial step is the capture of a defined amount of virus capsid particles on a first solid phase. The second step is lysis of the capsid to release the virus DNA from the first solid phase into a lysis solution. After separating the lysis solution from the first solid phase, the third step is contacting the lysis solution with a second solid phase. The second solid phase captures total DNA derived from the captured capsid. The present invention is also directed to a method for measuring the percentage of full virus capsid, comprising first determining the ssDNA concentration in viruses, and then converting the ssDNA concentration to percentage of full virus capsid using a calibration curve having DNA concentration plotted against standards of % of full capsids.

This invention provides an aminoisoquinoline derivative and its application in the preparation of antiviral drugs. The invention reveals that the aminoisoquinoline derivative exhibits significant inhibitory effects against various RNA and DNA viruses, demonstrating broad-spectrum activity. This small-molecule inhibitor has low toxicity and does not affect the normal growth of host cells. It shows good antiviral efficacy even at low concentrations. The results of this invention indicate that the compound has the potential to be used in the preparation of antiviral drugs and has promising clinical application prospects.

Disclosed are methods and compositions for treating infections caused by DNA viruses, including symptoms of the infections. The infections can be co-infections of the DNA viruses and other viruses. The methods, for example, can include administering pharmaceutical compositions comprising pipendoxifene disclosed herein to a patient in need.

The invention relates to a primer probe set for HBV (hepatitis B virus) in-vitro diagnosis, which comprises an internal standard primer probe set and a target primer probe set which are amplified in the same environment, and the internal standard primer probe set and the target primer probe set are configured as follows: the difference between the target probe and the internal standard probe is not more than 5 DEG C according to the fusion degree; the melting temperature of the probe of the internal standard is 5-10 DEG C higher than the melting temperature of the upstream and downstream primers of the internal standard; the probe melting temperature of the target is set to be 5-10 DEG C higher than the melting temperature of upstream and downstream primers of the target. According to the technical scheme, through three-dimensional technology coupling of melting temperature cooperative control, amplification kinetics synchronous optimization and sequence structure differentiation design, a comparison test of homologous serum and a plasma sample is completed aiming at the plasma sample in clinical verification, the positive coincidence rate, the negative coincidence rate and the total coincidence rate are 99.49%, 86.67% and 98.57% respectively, and the positive coincidence rate, the negative coincidence rate and the total coincidence rate are both 99.49%, 86.67% and 98.57% respectively. The internal standard designed by the technology can be further expanded to the field of detection of various RNA / DNA viruses including HIV-1, and a standardized solution is provided for development of molecular diagnosis kits.

The application provides a DNA virus tracer coated with a protein by an EDC covalent coupling method and a preparation method and application thereof. The DNA virus tracer coated with the protein of the application is composed of a core, a shell and a protein shell coated on the shell; the core is a SiO2 nanosphere with adsorbed nucleic acid on the surface, a layer of SiO2 shell is coated on the outside of the core, the surface of the shell is modified by carboxylation, and the shell is formed by covalently coupling the protein through EDC. The novel DNA virus tracer provided by the application can effectively protect the coding DNA, facilitate subsequent quantitative detection and analysis, effectively ensure that the outermost shell of the tracer is completely composed of the selected protein, and make the surface characteristics and migration characteristics of the tracer closer to the target virus.

Disclosed herein are 3,4-didehydro- and 3′-deoxy-3,4-didehydro-compounds and pharmaceutical compositions thereof. Methods of use of these pharmaceutical compositions include those for treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SAR-CoV-2, EBV, BKV, JCV and HCMV.

Probe sets capable of detecting pathogen nucleic acids in a sample are described. The probe set can be provided on a solid support, such as a microarray. Methods of detecting pathogen nucleic acids in a sample using the probe set are also provided. In some examples, the probes and methods are capable of detecting one or more RNA viruses, one or more DNA viruses, one or more bacterial nucleic acids, and / or one or more protozoan nucleic acids in a sample.

The invention discloses an antiviral polypeptide and application thereof. The amino acid sequence of the polypeptide is shown as SEQ ID NO: 1 or 2. The invention discovers that the antiviral polypeptide shows remarkable broad-spectrum inhibitory activity on DNA (deoxyribonucleic acid) virus (HSV-1), RNA (ribonucleic acid) virus (H1N1) and enveloped virus (VSV), and the inhibition rates of the antiviral polypeptide on the DNA virus (HSV-1), the RNA virus (H1N1) and the enveloped virus (VSV) respectively reach 50.54%-75.18%, 73.06%-96.30% and 64.78%-98.68% under the concentration of 10 mu M. Meanwhile, the polypeptide has excellent safety, the half toxicity concentration in each cell line is higher than 50 mu M, and the cell survival rate under the effective antiviral concentration exceeds 90%. The invention effectively overcomes the technical defects of narrow spectrum, easy generation of drug resistance and insufficient safety of the existing antiviral drug, and provides an important candidate molecule for developing a new generation of antiviral drugs.

In various embodiments methods of utilizing gene drive constructs in asexual organisms such as viruses are provided. In certain embodiments the methods involve transfecting or infecting a cell with a modified DNA virus containing a gene drive construct; and infecting the cell with the target virus where the genome of said target DNA virus is modified by insertion of the gene drive construct into the genome of the target DNA virus and a population of modified target viruses (containing the gene drive construct) is produced.

The invention relates to the technical field of medicines, in particular to application of DNMT3L gene coded protein in preparation of antiviral drugs, the DNMT3L coding gene is proved to have the effect of inhibiting replication and transcription of linear double-stranded DNA viruses or single-stranded negative-stranded RNA viruses, and analysis shows that cells over-expressing the DNMT3L coding gene can promote interferon expression, so that the anti-virus effect of the DNMT3L coding gene is improved, and the anti-virus effect of the DNMT3L coding gene is improved. According to the present invention, the DNMT3L coding gene is constructed into the overexpression plasmid by using the molecular biology method so as to significantly inhibit the replication of the linear double-chain DNA virus or the single-strand negative-chain RNA virus, and the DNMT3L coding gene is overexpressed in the host cell by using the vector so as to enhance the cell antiviral ability;

The present invention addresses the problem of providing a novel environmental symbiotic infection inhibitor against infectious disease viruses (RNA virus and DNA virus). The present invention provides a virus infection inhibitor comprising a microorganism of the genus Caldibacillus and a microorganism of the genus Paenibacillus.

A combination therapeutic strategy employs multiple oncolytic viruses (OVs), grouped and administered based on their virological properties, tumor selectivity, and distinct antigen profiles, to treat malignant tumors. Representative groupings may include members of flaviviruses, each contributing distinct immune modulation and the same modes of tumor cell killing. A predefined treatment schedule involves sequential or concurrent administration of antigenically diverse OVs in multiple cycles, reducing cross-neutralization and sustaining cytolytic pressure on tumors. A pre-characterized OV panel, comprising members from a virus family, RNA and DNA viruses, both wild-type and genetically engineered, serves as a flexible resource for customizing treatment regimens by tumor type, immune landscape, and therapeutic goals. This platform establishes a rational framework for combination OV therapy with improved durability, safety, and clinical effectiveness.

The present invention belongs to the technical field of antiviral drugs, and particularly relates to the application of astaxanthin in the preparation of antiviral products. The viruses include DNA viruses, positive single-stranded RNA viruses, and single-stranded negative-strand RNA viruses. Through in vitro and in vivo experiments, the present invention has confirmed that astaxanthin can inhibit virus adsorption and internalization, reduce the damage of the virus to the cell membrane structure and function, astaxanthin can inhibit virus invasion, and directly reduce the virus titer in animals. The research results of the present invention expand the scope of the efficacy of astaxanthin, and for the first time confirm that astaxanthin can prevent and treat virus-induced infections and diseases.

This invention belongs to the technical field of virus detection, specifically relating to a PCR detection kit for the simultaneous detection of four DNA viruses in waterfowl and its application. The PCR detection primer set for the simultaneous detection of four DNA viruses in waterfowl of this invention is the optimal primer set obtained through experimental screening. The kit composed of these primers can rapidly and specifically amplify and diagnose Muscovy duck parvovirus, duck plague virus, duck adenovirus type 3, and duck circovirus simultaneously, exhibiting high specificity and sensitivity. It can accurately and rapidly identify MDPV, DPV, DAdV-3, and DuCV, and can complete quantitative real-time PCR detection in approximately 50 minutes. The kit is simple and practical to operate, achieving efficient simultaneous detection of four viruses, shortening the detection cycle, increasing sensitivity by 10-1000 times, significantly improving early disease diagnosis capabilities, significantly reducing the misdiagnosis rate of diseases in poultry farms, and contributing to the sustainable development of the poultry farming industry.

The invention discloses a multiplex fluorescent quantitative PCR (Polymerase Chain Reaction) detection reagent for synchronously detecting four DNA (Deoxyribose Nucleic Acid) viruses related to infectious infertility. The detection reagent comprises specific primers and probes aiming at human microviruses, adenoviruses, polyoma viruses and adeno-associated viruses; the multiple fluorescence detection method used in the invention not only can synchronously detect four infectious DNA viruses in a single reaction tube, but also can simultaneously measure the load of the viruses, and has great value for researching infectious clinical diseases. The reagent disclosed by the invention has the characteristics of strong specificity, high sensitivity, good stability, simplicity in operation, less time consumption and the like, and can greatly improve the detection efficiency and reduce the detection cost when the method is used for performing large-scale clinical screening on the infection of the four viruses; meanwhile, the detection result can also provide important reference for formulating an individualized treatment scheme, so that the kit has important clinical application value and social significance for realizing symptomatic medication and improving the treatment effect.

This invention relates to the field of pharmaceutical technology, specifically to the application of 3-hydroxydecanoic acid in the preparation of antiviral drugs. In cell experiments, 3-hydroxydecanoic acid showed significant inhibitory effects on a variety of viruses, including RNA viruses (BEFV and BVDV) and DNA viruses (HSV-1 and BoHV-1), indicating that it has inhibitory effects on multiple viruses, is less likely to induce drug resistance, and has the advantage of broad-spectrum antiviral activity.

The invention relates to a non-guanidine salt type compatible nucleic acid extraction virus preservation solution as well as a preparation method and application thereof, and the virus preservation solution comprises P (HEMA-BAMPD hydrochloride), a buffer agent, a chelating agent, a saccharide stabilizer and an osmotic pressure regulator. The P (HEMA-BAMPD hydrochloride) is used for replacing guanidine salt and small molecule quaternary ammonium salt, the inactivation rate effect on enveloped RNA / DNA viruses such as SARS-CoV-2 viruses and influenza viruses is good, no irritation is generated, and the method is friendly to operators and the environment; the macromolecular structure realizes multi-point adsorption and has strong organic matter interference resistance, and a small amount of blood, sputum and other components in the sample do not influence the inactivation effect. Moreover, the P (HEMA-BAMPD hydrochloride), the chelating agent and the saccharide stabilizer have a synergistic effect, so that the activities of RNase and DNase can be effectively inhibited.

Macrophages (Mφ) are crucial for pathogen detection and elimination, and also serve as a microenvironment for replication of multiple infectious pathogens. This delicate balance between viral replication and antiviral response remains largely unknown at the molecular level. Addressing this issue is physiologically important given the persistent threat posed by emerging viral pathogens. Here, we demonstrate that GAS7 expression within macrophages restricts the replication of viral pathogens belonging to all major viral groups. We show that the antiviral activity of GAS7 exists even under conditions where the classical antiviral response mediated by type I interferon is neutralized. In particular, we show that in human monocyte-derived macrophages, silencing of GAS7 boosts the replication of multiple viral pathogens representing most relevant viral groups. These include the retroviruses HIV-1 (human immunodeficiency virus type 1) and HIV-2 (human immunodeficiency virus type 2), the RNA viruses Zika virus (positive-sense single-stranded RNA), Sindbis virus (single-stranded positive-sense RNA), Sendai virus (negative-sense single-stranded RNA), VSV virus (negative-sense single-stranded RNA), and measles virus (negative-sense single-stranded RNA), and the DNA virus HSV-1 virus (double-stranded DNA). Importantly, the antiviral activity of GAS7 is present even under conditions where type I interferon is neutralized by the addition of the B18R protein (which efficiently blocks the type I receptor). Furthermore, the inventors demonstrate that by forcing macrophages to overexpress GAS7, they are further protected from HIV-1 infection compared to cells expressing this factor at normal levels. Therefore, the present invention relates to the modulation of GAS7 expression and / or activity for modulating viral replication in macrophage populations.

The invention belongs to the technical field of virus detection, and discloses a reaction solution for DNA virus and RNA virus detection, the reaction solution is a reaction solution containing acetate, acetate salt is introduced as an ionic reaction system, the specificity of a one-step method RT-PCR amplification system is greatly improved, and the specificity of the one-step method RT-PCR amplification system is greatly improved. The amplification inhibition phenomenon of the residual reverse transcriptase activity on a subsequent DNA template is greatly reduced, so that the kit has a good effect on DNA detection while being capable of detecting the RNA virus.

This invention belongs to the field of biomedicine and provides the application of LAPF in the preparation of antiviral drugs. This invention enhances lysosomal acidification in dendritic cells or macrophages by administering LAPF protein, nucleic acid molecules encoding LAPF, or their functional enhancers, thereby promoting TLR9 transport to lysosomes and activating the type I interferon pathway. Experimental results demonstrate that administering LAPF protein, nucleic acid molecules encoding LAPF, or their functional enhancers can significantly reduce the viral load of DNA viruses such as HSV-1, increase the survival rate of infected mice, and enhance IFN-α / β production, exhibiting a good antiviral immune-enhancing effect.

The invention discloses application of 2-hydroxyisobutyric acid in preparation of a medicine for treating virus infection, and relates to the technical field of medicines. The invention discloses 2-hydroxyisobutyric acid which can be used for remarkably improving the antiviral activity of interferon I (Interferon, IFN). Type I interferon is a main medicine for clinically treating infection of viruses such as VSV and HIN1. Cytology experiments prove that 2-hydroxyisobutyric acid promotes the IFN-mediated antiviral capacity by promoting expression of IFN-induced interferon stimulating genes (ISGs), so that infection of various RNA viruses and DNA viruses is remarkably inhibited. Meanwhile, the function of the 2-hydroxyisobutyric acid also depends on 2-hydroxyisobutyrylation modification of the IRF9 protein. The 2-hydroxyisobutyric acid can be combined with IFN to treat infection of various viruses such as clinical VSV and H1N1, and the broad-spectrum antiviral curative effect of the clinical IFN is improved.

The invention discloses a triple RT-qPCR (Reverse Transcription-Quantitative Polymerase Chain Reaction) method and a kit for simultaneously detecting IMNV (Immunodeficiency Virus), CMNV (Cytomegalovirus) and DIV1 (Deoxyribose Immunodeficiency Virus According to the invention, PCR primers and TaqMan probes for detecting IMNV, CMNV and DIV1 are respectively designed, and the nucleotide sequences of the PCR primers and TaqMan probes are shown as SEQ ID NO: 1-9. The primer and the probe can be used for simultaneously qualitatively and quantitatively detecting the infectious muscle necrosis virus, the secretly death nodavirus and the full-eye iridovirus 1 through a triple RT-qPCR (Reverse Transcription-Quantitative Polymerase Chain Reaction) method. According to the invention, common detection of RNA virus and DNA virus is realized for the first time, the kit has the characteristics of high efficiency and convenience, and the advantages of high sensitivity, high specificity and quantitability, and meanwhile, due to the addition of the molecular crowding agent, the detection efficiency and detection speed of medium and low-concentration virus load can be effectively improved, and the detection cost is reduced. The invention provides a convenient and reliable detection method and product for early monitoring, early warning and diagnosis of the three virus diseases of the penaeus vannamei boone.

The invention relates to application of asparaginase in preparation of anti-inflammatory drugs, and belongs to the technical field of biological medicines. The invention discovers and discloses a new application of asparaginase in preparation of anti-inflammatory drugs for the first time. Experiments prove that the asparaginase affects the combination of asparaginase and an important linker molecule TBK1 in innate immunity by reducing the content of asparaginase in cells; according to the present invention, the asparaginase is used as the anti-inflammatory drug, and further influences the aggregation and the trans-self-phosphorylation of TBK1, such that the kinase activity of TBK1 is reduced, and the activation of the TBK1 downstream signal channel is inhibited, such that the generation of IFN-beta in the macrophage after DNA virus and RNA virus infection is significantly reduced, the replication of DNA and RNA viruses in the macrophage is promoted, and the specific anti-inflammatory effect of the asparaginase is proved, and the asparaginase can be used for preparing the anti-inflammatory drug.

The invention discloses a sweet potato autophagy related protein IbAIP5 as well as a coding gene and application thereof. Relates to the technical field of biology. Amino acid and nucleotide sequences and uses thereof are provided. According to the invention, a sweet potato autophagy core gene IbATG8f is used as a bait for screening sweet potato yeast double impurity libraries to obtain the new protein IbAIP5. And a virus-induced vector of the silent IbAIP5 gene is constructed. After the IbAIP5 silenced sweet potato plant is inoculated with the virus, the IbATG8f expression quantity and the SPLCV virus content are obviously reduced, and the SPFMV virus content and the SPCSV virus content are increased. It is shown that by inhibiting expression of IbAIP5 through a gene silencing means, the resistance of sweet potatoes to main DNA viruses SPLCV can be improved, the resistance to main RNA viruses SPFMV and SPCSV can be reduced, and contributions are made to research of sweet potato virus diseases, providing of resistant strains and sensitive strains and research of sweet potato antiviral breeding.

The invention discloses application of metformin in preparation of antiviral drugs, and relates to the technical field of molecular biology. Metformin can significantly inhibit the replication of a variety of RNA viruses and DNA viruses, and is verified in a variety of cell lines and mice. The invention illustrates that metformin promotes interferon-mediated antiviral ability by up-regulating expression of ISGs induced by IFN-I, and provides a new strategy for research and development of broad-spectrum antiviral drugs. Metformin is used as a clinical common drug and has low toxicity. Therefore, the metformin is expected to become a safer broad-spectrum antiviral drug for improving the antiviral activity of clinical interferon.

The application discloses a method for identifying DNA viruses in organisms based on high-throughput sequencing data, and the method comprises the following steps: taking a biological sample derived from the organism as a to-be-tested sample, performing high-throughput sequencing on the to-be-tested sample, and obtaining sequencing data in a FastQ file format; performing analysis and identification by using the sequencing data; and then identifying the DNA viruses in the to-be-tested sample. The method does not need to rely on metagenomic sequencing, can accurately identify the DNA viruses by using sequencing data of second-generation sequencing (high-throughput sequencing), avoids the generation of false positives, and greatly improves the utilization rate of sample sequencing data.

The invention discloses application of Momordin-Ic and I-type interferon in preparation of antiviral drugs, and relates to the technical field of molecular biology. It is found that Momordin-Ic has a significant antiviral function, can significantly inhibit replication of various RNA viruses and DNA viruses, and is verified in various cell lines and mice. Compared with the single use of the I-type interferon, the combination of the Momordin-Ic and the I-type interferon can further enhance the antiviral activity of the drug. Therefore, Momordin-Ic is expected to become a broad-spectrum antiviral drug for improving the antiviral activity of clinical interferon.

The present application relates to a kind of non-guanidine salt type compatible nucleic acid extraction virus preservative and preparation method and application, the virus preservative, including P (HEMA-BAMPD) hydrochloride, buffer, chelating agent, saccharide stabilizer and osmotic pressure regulator.The present application replaces guanidine salt and small molecule quaternary ammonium salt with P (HEMA-BAMPD) hydrochloride, and the inactivation rate effect of SARS-CoV-2 virus, influenza virus and other envelope type RNA / DNA viruses is good, and there is no irritability, and it is friendly to operating personnel and environment;Polymer structure realizes multiple point adsorption, and the ability of resistance to organic interference is strong, and a small amount of blood, sputum and other components in sample do not affect inactivation effect.Moreover, P (HEMA-BAMPD) hydrochloride, chelating agent and saccharide stabilizer synergistic effect can effectively inhibit RNase, DNase activity.

According to the microfluidic single RNA virus genome amplification method based on the RT-BST system, an RT-BST amplification system is introduced into a microfluidic liquid drop system, reverse transcription and strand displacement amplification of a single RNA virus in liquid drops are achieved for the first time through Bst DNA polymerase, and the technical problems that an RNA template is unstable, the amplification efficiency is low and the coverage rate is insufficient are solved. According to the RT-BST technology, the continuous reaction from RNA to cDNA and then to whole genome amplification is completed in a single droplet, the experimental process is greatly simplified, pollution and loss caused by multi-step operation or sample transfer are avoided, and the detection sensitivity and the result reliability are remarkably improved. Compared with a traditional MDA amplification technology mainly suitable for DNA viruses, the RT-BST method disclosed by the invention shows excellent applicability to RNA viruses and shows broad-spectrum compatibility.